In the STEP 1 semaglutide trial (Wilding et al., NEJM , 2021) and the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM , 2022), nausea affected roughly 44% of semaglutide patients and about 24% of tirzepatide patients at the maximum dose
Quality assessment and critical appraisal for the systematic review of the included studies The methodological quality of the included studies was evaluated independently by two reviewers using the Study Quality Assessment Tools developed by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), tailored to the design of each included study
Alcohol also dehydrates the body, which compounds the dehydration risk that Retatrutide already creates
After Ozempic, the market is moving toward obesity-specific injectables, oral GLP-1 drugs, dual agonists, triple agonists, amylin combinations, and cardiometabolic platform therapies
Building sustainable habits around eating and activity
10.1038/npp.2014.153 4 BajajJ